A global phase 2 trial

for children with achondroplasia (ACH)

Contact us to learn more!

What is ACcomplisH?

The ACcomplisH Trial is a global phase 2 clinical trial evaluating the safety and efficacy of TransCon™ CNP, an investigational treatment for children with achondroplasia (ACH) designed to provide continuous exposure to C-type natriuretic peptide (CNP) with once-weekly administration. For a list of participating countries and sites, please see ClinicalTrials.gov.

Who can participate?

Pre-pubertal children 2 to 10 years of age with ACH are invited to screen for trial eligibility.

What will happen during the trial?

After enrollment into the trial, participants will be randomly assigned to receive TransCon CNP or placebo in a 3:1 ratio. This means for every 4 participants, 3 will be randomly assigned to receive TransCon CNP and 1 will receive placebo. The randomization process to determine which medicine participants will receive is done via a computer system.

  • Participants and their doctors will not know who has been assigned to each group
  • Participants will receive either TransCon CNP or placebo once a week for 12 months (52 weeks)

Both study medicines are given with a small needle that is inserted under the skin. Participants who successfully complete the ACcomplisH Trial may have the opportunity to receive TransCon CNP in a long-term safety trial.

Is there a fee to participate?

  • No, there is no fee to participate in the ACcomplisH Trial
  • Trial-related costs for participants will be covered by Ascendis Pharma for the entire duration of the trial, including:
    • TransCon CNP or placebo
    • Laboratory tests
    • Other trial procedures
  • Reimbursement for time and travel expenses may be available in accordance with local regulations
Contact us to learn more

More information can be found at ClinicalTrials.gov

About the sponsor

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we're utilizing our TransCon technologies to create new and potentially best-in-class therapies. Our technology is being applied in three out of three of our rare disease endocrinology therapeutics programs.

TransCon CNP is an investigational agent.

ACH = achondroplasia; CNP = C-type natriuretic peptide.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.

©September 2019 Ascendis Pharma A/S.